Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-20T02:28:12.054Z Has data issue: false hasContentIssue false
  • English
  • Français

Clozapine

Published online by Cambridge University Press:  02 January 2018

J. Cutting  and
A. Reveley
J. Cutting
Affiliation:
The Bethlem Royal Hospital and The Maudsley Hospital
A. Reveley
Affiliation:
The Bethlem Royal Hospital and The Maudsley Hospital
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

On several occasions in the last ten years, when interviewed by a market researcher about future developments in the treatment of schizophrenia, we have said that the biggest problem in the drug management of schizophrenia is compliance. We believed that if drug companies could manufacture an injectable neuroleptic lasting six months, then many of our problems would be over. Compared with this, the benefits of a new neuroleptic preparation appeared to be trivial.

Type
Expert opinion
Information
Psychiatric Bulletin , Volume 15 , Issue 10 , October 1991 , pp. 617
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1991
Submit a response

eLetters

No eLetters have been published for this article.